已发表论文

Erastin 对铁死亡的作用及其在癌症治疗中的前景

 

Authors Zhao Y, Li Y, Zhang R, Wang F, Wang T, Jiao Y

Received 22 March 2020

Accepted for publication 14 May 2020

Published 11 June 2020 Volume 2020:13 Pages 5429—5441

DOI https://doi.org/10.2147/OTT.S254995

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Federico Perche

Abstract: Erastin was initially discovered as a small molecule compound that selectively kills tumor cells expressing ST and RASV12 and was later widely investigated as an inducer of ferroptosis. Ferroptosis is a recently discovered form of cell death caused by peroxidation induced by the accumulation of intracellular lipid reactive oxygen species (L-ROS) in an iron-dependent manner. Erastin can mediate ferroptosis through a variety of molecules including the cystine-glutamate transport receptor (system XC), the voltage-dependent anion channel (VDAC), and p53. Erastin is able to enhance the sensitivity of chemotherapy and radiotherapy, suggesting a promising future in cancer therapy. We hope that this review will help to better understand the role of erastin in ferroptosis and lay the foundation for further research and the development of erastin-based cancer therapies in the future.
Keywords: erastin, ferroptosis, system XC, p53, VDAC, cancer




Figure 3 The relevant pathways of ferroptosis induced by erastin.